{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:50:43Z","timestamp":1781207443799,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.talanta.2023.125173","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:36:59Z","timestamp":1694014619000},"page":"125173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Improvement of serum sample preparation and chromatographic analysis of nusinersen used for the treatment of spinal muscular atrophy"],"prefix":"10.1016","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7092","authenticated-orcid":false,"given":"Sylwia","family":"Studzi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Szymarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mazurkiewicz-Be\u0142dzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2023.125173_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ymthe.2020.12.022","article-title":"Clinical applications of single-stranded oligonucleotides: current landscape of approved and in-development therapeutics","volume":"29","author":"Scharner","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.talanta.2023.125173_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.talanta.2023.125173_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.talanta.2023.125173_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.talanta.2023.125173_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/bs.pmch.2018.12.003","article-title":"Rewriting the (tran)script: application to spinal muscular atrophy","volume":"58","author":"Ratni","year":"2019","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.talanta.2023.125173_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mas.21641","article-title":"Bioanalysis and biotransformation of oligonucleotide therapeutics by liquid chromatography-mass spectrometry","volume":"40","author":"Sutton","year":"2021","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.talanta.2023.125173_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jchromb.2018.05.025","article-title":"Review on sample preparation methods for oligonucleotides analysis by liquid chromatography","volume":"1090","author":"Nuckowski","year":"2018","journal-title":"J. Chromatogr. B"},{"issue":"4","key":"10.1016\/j.talanta.2023.125173_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.talanta.2023.125173_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/chromsci\/bmz114","article-title":"Hydrophilic interaction in solid phase extraction of antisense oligonucleotides","volume":"58","author":"Nuckowski","year":"2020","journal-title":"J. Chromatogr. Sci."},{"issue":"21","key":"10.1016\/j.talanta.2023.125173_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.4155\/bio-2019-0117","article-title":"LC-MS quantification of oligonucleotides in biological matrices with SPE or hybridization extraction","volume":"11","author":"Sips","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.talanta.2023.125173_bib11","article-title":"Application of hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for the retention and sensitivity studies of antisense oligonucleotides","volume":"1622","author":"Kaczmarkiewicz","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2023.125173_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.omtn.2019.07.006","article-title":"Metabolite profiling of the antisense oligonucleotide eluforsen using liquid chromatography-mass spectrometry","volume":"17","author":"Kim","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.talanta.2023.125173_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10337-019-03844-4","article-title":"Ultra high performance reversed phase liquid chromatography hyphenated with ESI-Q-TOF-MS for the analysis of unmodified and antisense oligonucleotides","volume":"83","author":"Studzi\u0144ska","year":"2020","journal-title":"Chromatographia"},{"key":"10.1016\/j.talanta.2023.125173_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.462860","article-title":"Effect of ion-pairing reagent hydrophobicity on liquid chromatography and mass spectrometry analysis of oligonucleotides","volume":"1666","author":"Donegan","year":"2022","journal-title":"J. Chromatogr., A"},{"key":"10.1016\/j.talanta.2023.125173_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2023.100079","article-title":"Separation of therapeutic oligonucleotides using ion-pair reversed-phase chromatography based on fundamental separation science","volume":"3","author":"Fornstedt","year":"2023","journal-title":"J. Chromatography Open"},{"key":"10.1016\/j.talanta.2023.125173_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.463823","article-title":"Development of a unified gradient theory for ion-pair chromatography using oligonucleotide separations as a model case","volume":"1691","author":"Enmark","year":"2023","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2023.125173_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462269","article-title":"Selectivity limits of and opportunities for ion pair chromatographic separation of oligonucleotides","volume":"1651","author":"Enmark","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2023.125173_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4155\/bio.14.94","article-title":"LC-MS of oligonucleotides: applications in biomedical research","volume":"6","author":"Basiri","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.talanta.2023.125173_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710166","article-title":"Development of the method for nusinersen and its metabolites identification in the serum samples of children treated with Spinraza for spinal muscular atrophy","volume":"23","author":"Studzi\u0144ska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.talanta.2023.125173_bib20","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1007\/s00216-020-02878-0","article-title":"Studying in vitro metabolism of the first and second generation of antisense oligonucleotides with the use of ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry","volume":"412","author":"Kilanowska","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2023.125173_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.124224","article-title":"A simple and green solid phase extraction method for oligonucleotides using adsorbent with amino and carboxylic moieties","volume":"255","author":"Studzi\u0144ska","year":"2023","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2023.125173_bib23","doi-asserted-by":"crossref","first-page":"96389","DOI":"10.1039\/C6RA17704B","article-title":"Dipeptide-bonded stationary phases for hydrophilic interaction liquid chromatography","volume":"6","author":"Skoczylas","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.talanta.2023.125173_bib24","doi-asserted-by":"crossref","first-page":"16221","DOI":"10.1039\/D0RA01620A","article-title":"Attachment of hybridizable oligonucleotide to silica support and its application for selective extraction of unmodified and antisense oligonucleotides from serum samples","volume":"10","author":"Studzi\u0144ska","year":"2020","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.talanta.2023.125173_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA Approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.talanta.2023.125173_bib26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/elps.201300269","article-title":"Comparison of mobile-phase systems commonly applied in liquid chromatography-mass spectrometry of nucleic acids","volume":"35","author":"Erb","year":"2014","journal-title":"Electrophoresis"},{"key":"10.1016\/j.talanta.2023.125173_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s13361-016-1500-3","article-title":"The role of fluorinated alcohols as mobile phase modifiers for LC-MS analysis of oligonucleotides","volume":"28","author":"Basiri","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.talanta.2023.125173_bib28","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.1016\/j.chroma.2009.07.020","article-title":"Modeling of thermal processes in high pressure liquid chromatography: I. Low pressure onset of thermal heterogeneity","volume":"1216","author":"Kaczmarski","year":"2009","journal-title":"J. Chromatogr., A"},{"key":"10.1016\/j.talanta.2023.125173_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461076","article-title":"Evaluating the advantages of higher heat conductivity in a recently developed type of core-shell diamond stationary phase particle in UHPLC","volume":"1625","author":"Le\u015bko","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2023.125173_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.talanta.2023.125173_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.talanta.2023.125173_bib32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.121.000751","article-title":"Antisense oligonucleotide in vitro protein binding determination in plasma, brain, and cerebral spinal fluid using hybridization LC-MS\/MS","volume":"50","author":"Guimaraes","year":"2022","journal-title":"Drug Metab. Dispos."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914023009244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914023009244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:32:05Z","timestamp":1729319525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914023009244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"alternative-id":["S0039914023009244"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2023.125173","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of serum sample preparation and chromatographic analysis of nusinersen used for the treatment of spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2023.125173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"125173"}}